Oxford Biomedica Crecimiento futuro
Future controles de criterios 5/6
Oxford Biomedica is forecast to grow earnings and revenue by 95.6% and 21% per annum respectively. EPS is expected to grow by 101.7% per annum. Return on equity is forecast to be -19.1% in 3 years.
Información clave
95.6%
Tasa de crecimiento de los beneficios
101.7%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 27.1% |
| Tasa de crecimiento de los ingresos | 21.0% |
| Rentabilidad financiera futura | -19.1% |
| Cobertura de analistas | Good |
| Última actualización | 28 Oct 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 212 | 8 | 26 | 37 | 8 |
| 12/31/2025 | 167 | -17 | 2 | 8 | 8 |
| 12/31/2024 | 130 | -39 | -26 | -21 | 8 |
| 6/30/2024 | 97 | -142 | -72 | -62 | N/A |
| 3/31/2024 | 93 | -150 | -55 | -45 | N/A |
| 12/31/2023 | 90 | -157 | -38 | -29 | N/A |
| 9/30/2023 | 104 | -110 | -24 | -11 | N/A |
| 6/30/2023 | 119 | -62 | -9 | 6 | N/A |
| 3/31/2023 | 130 | -50 | -19 | -3 | N/A |
| 12/31/2022 | 140 | -39 | -29 | -13 | N/A |
| 9/30/2022 | 133 | -32 | -31 | -17 | N/A |
| 6/30/2022 | 126 | -25 | -33 | -21 | N/A |
| 3/31/2022 | 134 | -3 | -9 | 2 | N/A |
| 12/31/2021 | 143 | 19 | 16 | 25 | N/A |
| 9/30/2021 | 139 | 19 | 15 | 26 | N/A |
| 6/30/2021 | 135 | 19 | 15 | 26 | N/A |
| 3/31/2021 | 111 | 6 | 2 | 15 | N/A |
| 12/31/2020 | 88 | -6 | -10 | 3 | N/A |
| 9/30/2020 | 77 | -9 | -16 | -1 | N/A |
| 6/30/2020 | 66 | -13 | -22 | -6 | N/A |
| 3/31/2020 | 65 | -14 | -26 | -5 | N/A |
| 12/31/2019 | 64 | -16 | -29 | -4 | N/A |
| 9/30/2019 | 64 | -12 | -26 | -4 | N/A |
| 6/30/2019 | 64 | -8 | -23 | -4 | N/A |
| 3/31/2019 | 65 | 0 | -10 | 4 | N/A |
| 12/31/2018 | 67 | 8 | 3 | 13 | N/A |
| 9/30/2018 | 62 | 4 | 9 | 18 | N/A |
| 6/30/2018 | 57 | 0 | 16 | 23 | N/A |
| 3/31/2018 | 47 | -5 | N/A | 13 | N/A |
| 12/31/2017 | 38 | -9 | N/A | 3 | N/A |
| 9/30/2017 | 34 | -10 | N/A | -1 | N/A |
| 6/30/2017 | 31 | -11 | N/A | -6 | N/A |
| 3/31/2017 | 29 | -14 | N/A | -4 | N/A |
| 12/31/2016 | 28 | -17 | N/A | -2 | N/A |
| 9/30/2016 | 26 | -16 | N/A | -1 | N/A |
| 6/30/2016 | 24 | -16 | N/A | -1 | N/A |
| 3/31/2016 | 20 | -15 | N/A | -7 | N/A |
| 12/31/2015 | 16 | -13 | N/A | -13 | N/A |
| 9/30/2015 | 15 | -12 | N/A | -12 | N/A |
| 6/30/2015 | 13 | -10 | N/A | -10 | N/A |
| 3/31/2015 | 13 | -9 | N/A | -8 | N/A |
| 12/31/2014 | 14 | -9 | N/A | -6 | N/A |
| 9/30/2014 | 11 | -9 | N/A | -8 | N/A |
| 6/30/2014 | 8 | -10 | N/A | -9 | N/A |
| 3/31/2014 | 7 | -11 | N/A | -10 | N/A |
| 12/31/2013 | 5 | -11 | N/A | -11 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: OXBD.F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Beneficios vs. Mercado: OXBD.F is forecast to become profitable over the next 3 years, which is considered above average market growth.
Beneficios de alto crecimiento: OXBD.F is expected to become profitable in the next 3 years.
Ingresos vs. Mercado: OXBD.F's revenue (21% per year) is forecast to grow faster than the US market (8.9% per year).
Ingresos de alto crecimiento: OXBD.F's revenue (21% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: OXBD.F is forecast to be unprofitable in 3 years.